Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA53-OS in p53 Wild-Type Solid Tumors
NCT06578624Phase 2Recruiting
- Sponsor
- Lamassu Bio
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of sa53-os in solid tumor, dedifferentiated liposarcoma (DDL), non-Hodgkin lymphoma (NHL), sponsored by Lamassu Bio. Started Mar 2025; status: recruiting.
02
Drugs
sa53-os
03
Conditions
solid tumordedifferentiated liposarcoma (DDL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06578624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578624.